“Today, patients want to get diagnosis and treatment faster with fewer visits to the doctor’s office. They want speedier and more comprehensive delivery of clinical services, be it laboratory tests, imaging, or other procedures.”
—Ralph Taylor, President, Sysmex America, Inc.
CEO Summary: To bring testing closer to patients, clinical laboratories will need to offer sophisticated point-of-care systems
CEO SUMMARY: In five months, Medicare officials will implement a new Part B clinical laboratory fee schedule based on private payer lab price data submitted by certain medical laboratories required to report that data. At this year’s Executive War College, the CEO of XIFIN, Inc., reported on her company’s analysis of the payer price data
AT LEAST 48 HOSPITALS, PHYSICIANS’ OFFICES, and ambulance companies in Britain’s National Health Service were among the many victims of a cyberattack Friday that affected tens of thousands of computers in as many as 150 countries, The New York Times reported. Hackers used malicious software developed by and stolen from the U.S. National Security Agency,
CEO SUMMARY: In the United States, medical labs have long recognized that paying over-market rates to lease phlebotomy space in physicians’ officers is an inducement and a violation of federal anti-kickback laws. In Australia, a law in 2010 that removed the cap on what labs could pay to lease phlebotomy space in physicians’ offices caused
Tougher times in the clinical lab testing market have claimed another lab company. On February 28, Artherotech, Inc., posted a notice on its website stating that it had closed permanently, as of that date. Along with its several hundred employees, Artherotech’s closure caught many lab executives by surprise. Founded in 1994, during the heyday of closed-panel
CEO SUMMARY: There is a new buyer for lab test data, creating an opportunity for labs to build a new revenue stream. Medivo, Inc., of New York, describes itself as a healthcare data analytics company whose mission is to unlock the power of lab data to improve health. It works with clinical labs and pathology
CEO SUMMARY: As 2016 approaches, nearly every lab organization is watching and waiting to learn how federal regulators at CMS and the FDA will move forward with plans to implement PAMA market reporting and regulation of laboratory-developed tests, respectively. Most knowledgeable observers expect that each government program will cost labs substantial amounts of money—from fee
CEO SUMMARY: For clinical laboratories and anatomic pathology groups willing to adapt to the evolving needs of the American healthcare system, there are many positive opportunities. That’s the view of a Wall Street investment bank that just published a report on the lab testing sector. The report on healthcare trends includes commentary about developments in cancer care, acceptance of personalized medicine, and the growing activity in direct-to-consumer lab testing.
CEO SUMMARY: Clinical laboratories of all sizes are poised to become the source of much of a hospital or health system’s “big data.” At many academic center labs, greater use of genetic and molecular testing requires that more space and more staff be devoted to data management. At the same time, the latest generation of gene sequencing instruments and molecular analyzers are cheaper, faster, and more automated. These systems make it feasible for even smaller labs to offer sophisticated genetic tests.